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ABBREVIATIONS 
Bayley-III  Bayley Scales of Infant Development, Third Edition 
CCS Cognitive composite score  
DHA   Docosahexaenoic acid 
LCS Language composite score  
MCS Motor composite score  
UMP   Uridine-5-monophosphate 
VABS-II  Vineland Adaptive Behavior Scales, Second Edition 
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[Abstract] 
AIM To investigate whether neonates at risk for neurodevelopmental impairment have 
improved neurodevelopment after docosahexaenoic acid, choline, and uridine-5-
monophosphate supplementation versus controls. 
METHOD Recruitment was from UK neonatal units. Eligible for inclusion were infants born 
at less than 31 weeks’ gestation with a weight less than the ninth centile; infants born at less 
than 31 weeks’ gestation with a grade II or higher intraventricular haemorrhage/preterm 
white matter injury; infants born between 31 and 40 weeks’gestation plus 28 days with a 
grade II or higher intraventricular haemorrhage/preterm white matter injury, moderate or 
severe hypoxic ischaemic encephalopathy, or defined neuroimaging abnormalities. 
Treatment/control supplementation was for 2 years (double-blind, randomized, controlled 
design). Infants were stratified according to sex, gestation, and brain injury severity. Primary 
outcome was cognitive composite score (CCS) of the Bayley Scales of Infant Development, 
Third Edition (Bayley-III) at 24 months). Secondary outcomes were language composite 
score (LCS) of the Bayley-III, motor composite score (MCS) of the Bayley-III, and Vineland 
Adaptive Behaviour Scales, Second Edition (VABS-II) score.  
RESULTS Sixty-two neonates were recruited, 59 were randomized (34 males, 25 females). 
Fifty-three started supplementation. Most families found supplementation acceptable. The 
treatment group CCS-Bayley-III scores were non-significantly higher than controls (mean 
score difference at 24 months: 9·0; 95% confidence interval –0·2 to 18·2). Language and 
VABS-II scores, but not motor score, were non-significantly higher in the treatment group.  
INTERPRETATION Most families found supplementation feasible. Improved 
neurodevelopmental outcomes in the treatment group were not statistically significant. A 
larger multicentre trial exploration is warranted. 
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WHAT THIS PAPER ADDS 
 Dietary supplementation of neonates at risk of neurodevelopmental impairment is 
feasible. 
 No statistically significant neurodevelopmental advantages were identified for the 
treatment group compared to controls. 
 Treatment group cognitive and language advantage are of a clinically meaningful 
magnitude. 
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Rapid brain growth and development during the third trimester of pregnancy and the first 2 
years of life relies upon adequate macro- and micronutrient intake. Brain integrity and 
function depends upon specific membrane phospholipids and their fatty acids. 
Phosphatidylcholine is the most abundant brain phospholipid.1 The omega-3 fatty acid 
docosahexaenoic acid (DHA), choline (an amine), and uridine-5-monophosphate (UMP; a 
pyrimidine) combine to form phosphatidylcholine.2 DHA, choline, and uridine 
supplementation synergistically increases rodent brain phospholipids, synaptic components, 
functional brain connectivity, and cognitive performance.3  
Micronutrients, including zinc, the B vitamins, and iodine, also have important central 
nervous system roles. Zinc is important for neurogenesis, neuronal migration and 
synaptogenesis, and the metabolism of thyroid hormones.4 The B vitamins also support 
synaptogenesis and synaptic function. Iodine is necessary for thyroid hormone production; 
the neurodevelopmental consequences of hyopthyroidism are well recognized. After brain 
injury, plasticity may contribute to functional recovery, supported by the synaptic elements, 
extracellular matrix, and guidance molecules of the subplate.5  
Perinatal factors including extreme prematurity (gestational age <28wk), intrauterine 
growth restriction (birthweight <10th centile for gestational age), and term hypoxic ischaemic 
encephalopathy are associated with suboptimal neurodevelopmental outcomes and specific 
diagnoses, including cerebral palsy, epilepsy, visual impairment, intellectual disability, 
specific learning and attention difficulties, and neuropsychiatric conditions.6–9 A systematic 
review of early intervention on preterm cognitive and motor outcomes identified 
postintervention cognitive benefit in infancy and at preschool age, and postintervention motor 
benefit in infancy, although the effect size on motor benefit was small. Heterogeneity 
between studies prevents adequate comparisons between intervention methods, limiting the 
ability to draw conclusions about which intervention is most effective.10 A subsequent review 
specifically focusing on motor development interventions delivered by parents and 
continuing after discharge also favoured intervention, with the strongest effects below 6 
months corrected age; again, heterogeneity between studies limited interpretation.11 
Therapeutic hypothermia is the only intervention shown to improve mortality and 
neurodevelopmental outcomes after mild-to-moderate hypoxic ischaemic encephalopathy.12 
The Dolphin neonatal trial and parallel Dolphin infant trial13are the first to provide infants 
with risk factors for neurological impairment with the combination DHA, choline, and UMP 
at maximum permissible levels during brain development. We investigated whether treatment 
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group neurodevelopmental outcomes were improved versus controls, and if supplementation 
was feasible for parents and infants.  
 
METHOD 
The Dolphin neonatal trial was a randomized, double-blind, placebo-controlled trial of DHA, 
choline, and UMP, or control, supplementation in neonates with neurodevelopmental 
impairment risk factors. The full methodology is available in the published open-access trial 
protocol.14 
 
Participants 
All infants had neurological impairment risk factors. Eligible infants were born at less than 
31 weeks’ gestation with a birthweight less than the ninth centile; infants born at less than 31 
weeks’ gestation with a grade II or higher intraventricular haemorrhage/preterm white matter 
injury; infants born between 31 and 40weeks’ gestation and 28 days with a grade II or higher 
intraventricular haemorrhage/preterm white matter injury, moderate or severe hypoxic 
ischaemic encephalopathy, or defined neuroimaging abnormalities consistent with perinatal 
brain injury (see Table I).14 Variation in brain injury inclusion criteria for infants born at term 
and preterm reflects the predominant patterns of cerebral injury occurring at different stages 
of brain development through gestation.15 
Trial exclusion criteria were infants with major congenital malformation; underlying 
progressive neurological, genetic, or metabolic condition; severe hearing loss; gastrointestinal 
malabsorption; and cow’s milk or egg allergy.  
Recruitment was from three UK neonatal units: the John Radcliffe Hospital (Oxford), 
the Royal Berkshire Hospital (Reading), and Wexham Park Hospital (Slough). Eligible 
infants were identified by clinical teams with research team support (MJA and CM-J). 
Interested parents received a parent information sheet, followed by research team contact to 
answer queries approximately 48 hours later. Written informed consent was obtained from 
the parents or guardians of participating infants. Ethical approval for the study was granted 
by the Oxfordshire Research Ethics committee B.  
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After consent, participants were randomized by the University of Oxford’s Centre for 
Statistics in Medicine, using the minimization factors of sex, gestation (<31 weeks or 31–
40weeks and 28 days), and brain injury severity (normal-to-mild, moderate, or severe) 
identified by brain magnetic resonance imaging or cranial ultrasound scans,14 conducted as 
part of routine clinical care. The principal investigators and researchers conducting 
neurodevelopmental assessments were blind to group allocation. The trial dietician was not 
blinded, to ensure prompt identification of any side effects of supplementation. The trial 
administrator was blinded until the time of dietary intake data entry, when group allocation 
became clear. Unblinded team members did not discuss the infants’ treatment group with 
other team members or parents and had no role in data analysis. 
Randomized infants received treatment or control supplementation daily for 2 years 
from trial entry. The study supplements were produced and quality control checked by 
Nutricia Advanced Medical Nutrition (Utrecht, the Netherlands). The treatment supplement 
contained DHA (1% of total daily estimated fatty-acid intake), eicosapentaenoic acid, 
arachidonic acid, choline, UMP, cytidine monophosphate, vitamin B12, zinc, and iodine 
(Table II). Treatment and control supplements were produced on a background of infant 
formula; therefore, the control supplement also contained vitamins, minerals, and trace 
elements, and a small amount of choline. Infants received a 2g/kg/day supplement (maximum 
24g/day), for a total of 2 years from trial entry, or while compliant with the study protocol. 
Supplementation began once infants were on full milk feeds. The supplement was supplied as 
a combination of 2g, 3g, and 12g foil sachets to protect it from sunlight. The supplement was 
mixed with usual formula or expressed breast milk, or wet foods on weaning, and given 
orally, or through the child’s feeding tube. The trial dietician telephoned families every 2 
weeks initially, then as required, and visited every 3 months to assess adherence to and 
tolerance of the supplement, dietary macro- and micro-nutritional intake, growth, and advise 
on optimal macronutrient intake for both groups.  
Study assessment psychometric properties and administration are described in the trial 
protocol.14 The Bayley Scales of Infant Development, Third Edition (Bayley-III) were 
administered to infants at baseline, and at 12 months and 24 months in the child’s home by 
one of two trained assessors (MJA and CMJ). The Vineland Adaptive Behavior Scales, 
Second Edition (VABS-II) were administered to parents after Bayley-III assessment (MJA or 
CMJ). Neurophysiological and functional behavioural visual measures were performed at 
baseline, and at 6 months, 12 months, and 24 months. Occipito-frontal circumference was 
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measured using a Lasso-o tape measure at baseline then every 3 months. A mean from three 
occipito-frontal circumference measurements was calculated unless an infant was not 
compliant, in which case one confidently obtained measurement was accepted. Height, 
weight, and triceps skinfold thickness were measured every 3 months.14 
Dietary assessment occurred every 3 months, at home. Dietary history using food 
recall over the previous week was recorded, and used to advise families on optimal macro- 
and micronutrient intake. Dietary data were analysed using Dietplan 6 (Forestfield Software, 
Horsham, UK). 
Participant whole-blood fatty-acid samples were collected by heel prick onto a 
Guthrie card at baseline and at 24 months. Maternal whole-blood fatty-acid levels were 
collected by finger prick at baseline. Blood fatty-acid levels were analysed using the method 
of Marangoni et al.16  
The primary outcome was cognitive composite score (CCS) of Bayley-III after 
supplementation for 24 months. The Bayley-III is a standardized neurodevelopmental 
measure, with cognitive, language, and motor domains, for infants aged between 1 month and 
42 months.17 The Bayley-III composite score has a range of 40 to 160 (mean 100, SD 15) and 
is a normalized transformation of standardized scaled scores, composite scores, and centile 
ranks provided in the Bayley-III manual.  
Secondary neurodevelopmental outcomes included CCS-Bayley-III at 12 months, 
language composite score (LCS) of the Bayley-III and motor composite score (MCS) of the 
Bayley-III at 12 months and 24 months, and VABS-II standard adaptive score at 12 months 
and 24 months. The VABS-II Parent/Caregiver Rating Form is a standardized parent 
questionnaire regarding adaptive behaviour from birth to the age of 90 years.18 The measure 
provides a standard adaptive composite score standardized and normed for age (mean 100, 
SD 15), derived from standardized domain scores: communication, socialization, and daily 
living skills.  
 
Statistical analysis 
Statistical analyses were conducted according to the trial statistical analysis plan and 
performed using R version 3.2.1.19  
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Sample size was calculated for 80% power to detect a 12·5-point difference in CCS-
Bayley-III, at the 5% level for a two-tailed test. In total, a sample size of 48 participants were 
required, assuming a SD of 15. Assuming a 20% loss to follow-up the recruitment target was 
increased to a total of 60 infants. 
An intention-to-treat analysis included all infants as randomized who had Bayley-III 
data at baseline and at least one other time point (n=45). Change in CCS-Bayley-III from 
baseline was analysed at 12 months and 24 months of supplementation using mixed-effects 
linear regression to account for repeated measures over time, with model covariates of 
baseline CCS-Bayley-III, time point (12 months and 24 months postsupplementation), 
treatment group, an interaction between time point and treatment group, and minimization 
factors of brain injury severity (normal-to-mild/moderate/severe), gestation (<31wk/31–
42wk), and sex (male/female). No adjustment of p values for multiple end points was made.  
Analyses of secondary outcomes including LCS-Bayley-III, MCS-Bayley-III, and 
VABS-II score followed the procedure for the primary outcome analysis. Anthropometric 
measurements were converted to z-scores using the World Health Organization’s Child 
Growth Standards R ‘igrowup’ package for infants born at term,20,21 and the Microsoft Excel 
add-in LMSgrowth with UK preterm reference data for infants born preterm.22 Mixed-effects 
regression models were fitted to the data, and the fitted difference in means between 
treatment and control groups at 12 months and 24 months presented alongside 95% 
confidence intervals (CIs) and the associated two-sided p value for the overall effect of 
treatment.  
An independent data-monitoring committee, consisting of two consultant paediatric 
neurologists, an independent statistician, and the trial statistician, periodically oversaw trial 
progress and reviewed the results of an interim analysis at the midpoint of the trial.  
The trial was registered with the ISRCTN Registry (ISRCTN39264076). 
 
RESULTS 
Recruitment was carried out between September 1st, 2009 and January 9th, 2013. In total, 
258 families were identified as eligible, of which 126 families were approached. We received 
consent for 62 infants to participate: 59 were randomized (34 males, 25 females); one infant 
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died before randomization; and two withdrew after consent was given but before 
randomization. Fifty-three infants started supplementation. In total, 132 families of eligible 
infants could not be approached owing to factors including transfer to a non-participating 
district general hospital, death before approach, language barriers, and issues of parental 
capacity. The flow of participants is summarized in Figure 1.  
The baseline characteristics of the treatment and control group infants are shown in 
Table III. 
Infants who discontinued supplementation before 24 months and did not participate in 
subsequent follow-up assessments were considered to be withdrawals. There were a total of 
16 withdrawals over the 24 months (five from the treatment group and 11 from the control 
group). Eleven infants were withdrawn before 6 months. By 12 months, a total of 14 infants 
had withdrawn (four from the treatment group and 10 from the control group). Between 13 
months and 24 months two further infants withdrew. One further infant discontinued 
supplementation but continued with study assessments (data included in analysis). 
Withdrawal reasons were family circumstance, other appointments, cow’s milk protein 
intolerance, moving country/region, and the effect of comorbidity (predominantly epilepsy) 
on family life. 
Trial supplement intake varied between participants. Of the randomized infants, 39 
out of 59 (66%) completed full dose supplementation for 24 months; one infant completed 
approximately 50% dose for 24 months. Five infants completed full dose for at least 12 
months. Five infants completed between 8 weeks and 12 months of supplementation. Three 
infants were supplemented for less than 8 weeks before withdrawing. Six infants withdrew 
before supplementation started (one from the treatment group and five from the control 
group).  
After a protocol violation, one infant was randomized to the control group but 
received treatment supplement for 2 years; this child’s data are analysed with the control 
group. 
The long-chain polyunsaturated fatty acid levels in infants in the baseline treatment 
and control groups were similar. Mean 24-month blood DHA level was higher in the 
treatment group versus controls (relative percentage 0·009 [SD 0·006] and 0·004 [SD 0·002] 
respectively; p=0·002), as were mean 24-month eicosapentaenoic acid level (relative 
percentage 0·031 [SD 0·018] and 0·013 [0·006] respectively; p<0·001). 
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CCS-Bayley-III data were available for 55 out of 59 (93%) participants. Participants 
included in the intention-to-treat analysis had CCS-Bayley-III data at baseline and at 12 
months or 24 months (n=45; 24 from the treatment group and 21 from the control group). 
Mean baseline CCS-Bayley-III scores were similar for treatment group and control infants. 
At 12 months, mean CCS-Bayley-III scores were non-significantly higher for the treatment 
group than controls 85.2 (SD 18·1) versus 82·4 (SD 20 ·1) (mean modelled difference 4·4 
points, 95% CI –4·7 to 13·4). At 24 months, CCS-Bayley-III scores were also non-
significantly higher in the treatment group than in controls (87·7 [SD 20·4] vs 81·6 [SD 
18·5]; mean modelled difference 9·0 points, 95% CI –0·2 to 18·2 [p=0·13]; Table IV). There 
was no difference in treatment effect by visit (no interaction; χ2[1]=1·64 [p=0 ·20]) and no 
overall effect of treatment (χ2[1]=2 ·28 [p=0·13]).  
Post hoc analysis of the primary outcome data after removal of the minimization 
factors from the model did not change the overall findings (Table IV; mean modelled 
difference 3·7 points [95% CI –6·4 to 13·8] at 12 months and 8·3 points [95% CI –1·9 to 
18·6] at 24 months). There was no difference in treatment effect by visit (χ2[1]=1·62 [p=0·2]) 
and no overall effect of treatment (χ2[1]=14·4 [p=0·23]). A sensitivity analysis was 
performed to look at any differential effect of supplementation in infants with mild or 
moderate brain injury versus those with severe brain injury, in relation to primary outcome. 
When infants with severe brain injury were removed from analysis, the mean treatment group 
CCS-Bayley-III remained higher than controls at 24 months (9·25 [SD 19·9] vs 88·8 [SD 
14·0]; mean modelled difference 8·7 [95% CI –2·7 to 20·0]). 
To investigate whether the observed pattern of cognitive advantage in the treatment 
group could be the result of higher breastfeeding levels, the primary analysis was repeated, 
including a main effect for breastfeeding and an interaction term for breastfeeding and 
treatment, as well as adjusting for baseline Bayley-III cognitive score, treatment group, visit, 
treatment, and visit interaction, and the minimization factors of brain injury severity, sex, and 
gestational age at birth. Thirty-three infants (16 in the treatment group and 17 in the control 
group) were breastfed at baseline (partially or exclusively breastfed for any duration). There 
was no difference in treatment effect on CCS-Bayley-III at 24 months between those who 
were breastfed and those who were not (p=0·56).  
Mean LCS-Bayley-III scores were non-significantly higher for treatment compared 
with control infants at 12 months (77.6 [SD 14·6] vs 74·6 [SD 12·0]; modelled difference in 
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means 2·7 [95% CI –6·7 to 12·1] and 24 months (91·5 [SD 20·1] vs 83·2 [SD 19·6]; 
modelled difference in means 8·6 [95% CI –1·1 to 18 ·2]). There was no overall treatment 
effect (χ2[1]=1·57 [p=0·21]) or treatment effect by visit (χ2[1]=1·78 [p=0·18]; Table IV).  
As with the primary outcome measure of CCS-Bayley-III, post hoc analysis of the 
data without minimization factors produced similar results (Table IV; mean modelled 
difference 3·2 points [95% CI –6·2 to 12·7] at 12 months and 9·0 points [95% CI –0·6 to 
18·6] at 24 months). There was no difference in treatment effect by visit (χ2[1]=1·75 
[p=0·19]) and no overall effect of treatment (χ2[1]=1·87 [p=0·17]).  
Mean MCS-Bayley-III scores were similar at 12 months and 24 months for treatment 
and control groups (Table IV). 
Bayley-III composite domain standard scores by group and visit, plus unadjusted and 
adjusted analyses, are shown in Table IV.  
Regarding parent-reported data, mean VABS-II domain standard scores were non-
significantly higher in the treatment group compared with control group infants at 12 months 
(86·9 [SD 16·0] vs 84·6 [SD 13·6]; mean modelled difference 1·6. [95% CI –5·7 to  8·8]) 
and 24 months (92·3 [SD 10·8] vs 87·4 [SD 15·1]; mean modelled difference 4·4 [95% CI –
3·1 to 12·0]). There was no overall treatment effect (χ2[1]=0·69 [p=0·4]) or treatment effect 
by visit (χ2[1]=0·71 [p=0·4]).  
Reanalysis of VABS-II domain standard scores without minimization factors included 
in the model did not significantly alter the results. At 12 months the mean modelled treatment 
group score was 1·9 (95% CI –5·9 to 9·8) and at 24 months it was 4·6 (–3·5 to 12·7). There 
was no effect of treatment by visit (χ2[1]=0·60 [p=0·44]) and no overall effect of treatment 
(χ2[1]=0·73 [p=0·39]). 
Forest plots of Bayley-III primary and secondary outcome scores and VABS-II scores 
are shown in Figure 2. 
Owing to differential drop out of infants with normal-to-mild brain injury from the 
control group, the treatment group as a whole had a less severe brain injury profile. By 24 
months, there were 10 treatment group and three control group infants with normal-to-mild 
brain injury severity. There were similar numbers of infants with moderate brain injury (six 
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infants in the treatment group and nine in the control group) and severe brain injury (eight 
infants in the treatment group and seven in the control group) at 24 months.  
A comparison of occipito-frontal circumference between baseline and 24 months 
showed no significant differences between the treatment and control groups (modelled 
difference in mean z-score at 24 months 0·4; 95% CI –0·1 to 0·9 [p=0·19]). There was no 
between-group differences in height, weight, or triceps skinfold thickness at 12 months or 24 
months (data not shown). 
Overall, secondary outcome vision measures showed no differences between the 
treatment and control groups. Trial vision data will be reported separately (data not shown). 
There were no differences in the number of days ventilated nor in the number of 
infants who developed severe infection or necrotizing enterocolitis between treatment and 
control groups. 
 
DISCUSSION 
This novel trial is the first to provide all three phosphatide precursors (DHA, choline, and 
UMP) at maximum permissible levels to neonates at risk of neurodisability. Supplementation 
aimed to achieve DHA levels approaching the maximum naturally occurring levels in human 
breast milk. Previous studies have used relatively small doses of DHA for relatively short 
periods of time.23 Supplementation started around term, and continued throughout the first 2 
years of life – the period of maximal brain growth. Supplementation was acceptable to most 
parents and was continued for 2 years by the majority. 
No statistically significant differences in cognitive or language performance were 
identified between treatment groups. Despite this, mean treatment group cognitive and 
language scores were higher than in the control group. Similarly, parent-reported VABS-II 
domain standard scores were higher in the treatment group. The mean difference in CCS-
Bayley-III and LCS-Bayley-III are of a clinically significant magnitude – the between-group 
difference in primary outcome equates to a treatment effect size of 0·31. These effects do not 
result from macronutrient intake (optimized for both groups); energy and protein intakes 
were similar for the treatment and control groups and there were no treatment group 
differences in height or weight. Had the treatment group had better overall nutrition then this 
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should have been visible as improved treatment group growth parameters over the extended 
time frame of the study. Furthermore, there was no observed increase in head circumference 
(brain size) among infants in the treatment group; head circumference was similar at baseline 
and 24 months for both groups.  
The results of previous studies examining the neurocognitive effects of DHA 
supplementation during early infancy differ, possibly owing to variation in design. The DINO 
randomized control trial of high-dose DHA (1% of total daily fatty acids) supplementation in 
preterm neonates reported improvements in Bayley Scales of Infant Development, Second 
Edition Mental Development Index score in supplemented females (mean difference of 4·5 
points in adjusted analyses) but not males. There were fewer infants with impaired 
neurocognitive development in the treatment group compared with controls.24 Lucas et al. 
report cognitive advantage in infants born preterm at less than 30 weeks’ gestation fed a 
‘high-nutrient’ or ‘standard-nutrient’ formula milk (median supplementation 4 weeks), with a 
mean treatment advantage of 8·6 points in the Bayley Scales of Infant Development, Second 
Edition Mental Development Index at 18 months corrected gestational age.25 Bayley Scales 
of Infant Development, Second Edition performance was best in those infants with the 
highest intake of the ‘high-nutrient’ formula, in infants who were small for gestational age 
and in male infants.26 The ‘high-nutrient’ formula supplemented macro- and micronutrient 
intake; it is not possible to ascertain whether macro- or micronutrient supplementation singly 
or in combination resulted in the observed treatment group cognitive advantage. As 
macronutrient intake in the Dolphin control and treatment groups were comparable, any 
treatment advantage is not the result of improved overall nutritional status. The observed 
treatment advantage in the Dolphin neonatal trial is comparable with that reported by Lucas 
et al.26 Long-term follow-up of the cohort of Lucas et al. confirms lasting 
neurodevelopmental benefit in the treatment group at school age.27-30  
This novel multi-site trial recruited infants from UK National Health Service neonatal 
units. Retention was high: of the 53 families who started supplementation, 45 (85%) 
continued to at least 12 months. Infants were compliant with supplementation. Formal 
compliance measures were not included in this study as it was decided that study demands 
upon participating families were already high; however, supplementation led to higher 
relative blood DHA and eicosapentaenoic acid levels in the treatment group versus controls, 
suggesting treatment fidelity was acceptable. Formal compliance measures, such as the 
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recording of number of returned sachets, would be beneficial in any larger study. Outcome 
measurement was completed by one of two assessors.  
There are a number of challenges for the interpretation of the observed differences in 
mean CCS-Bayley-III and LCS-Bayley-III. There was heterogeneity regarding gestational 
age at birth and aetiology, anatomical location, and severity of brain injury. Minimization 
allowed reasonable comparison between intervention groups; however, larger numbers of 
infants and narrower inclusion criteria would further reduce heterogeneity between groups. 
Owing to the number of infants in this study, we could not control for all potential 
confounding factors, such as maternal education level, which, by chance, was higher in the 
treatment group than in the control group; this may have contributed to the treatment group 
neurodevelopmental advantage. Similarly, several other clinical risk factors may have 
contributed to group neurodevelopmental outcomes; however, there were no differences in 
the number of days ventilated nor in number of infants who developed severe infection or 
necrotizing enterocolitis between treatment and control groups. There were no observed 
treatment group differences in primary outcome measure between infants who were breastfed 
and those who were not, although statistical tests for interaction have a low power to detect 
differences.31 The effect of breastfeeding on treatment group outcome requires further 
exploration in any future trial. During the supplementation period, there were 
disproportionately more withdrawals of control infants within the mildest brain injury 
category, producing a more severe neuroanatomical brain injury profile across controls. 
Despite statistical modelling accounting for brain injury severity, the observed cognitive and 
language treatment group advantage may reflect the milder overall brain injury profile of the 
treatment group. 
Despite these challenges to interpretation, if the observed improvement in CCS-
Bayley-III for treated infants is replicated in a larger trial, this will have important 
implications for the treatment of infants at risk of neurological impairment, and for our 
understanding of the role of brain phosphatide precursors in neurodevelopment. The Dolphin 
cohort follow-up trials assessing the effects of combination nutritional supplementation in the 
preschool and school years will provide important long-term follow-up data.  
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Table I: Neuroimaging severity grading12 
 Normal/mild Moderate Severe 
Preterm injury 
cUSS 
 Normal 
 Grade I/II IVH 
 VIn <13mm at 
TEA or  
 VIn <97th centile 
for CGA 
 Grade III 
IVH 
 Non-cystic 
PVL 
 VIn 13–
15mm TEA 
or 
 VIn >97th 
centile but 
<4mm 
above 97th 
centile for 
CGA 
 Grade IV IVH 
 PVHI 
 Cystic PVL 
 Subcortical 
leucomalacia  
 VIn at TEA 
>15mm or 
 VIn >4mm 
above 97th 
centile for CGA 
 BG lesions 
 Focal infarction 
Term hypoxic 
ischaemic 
encephalopathy  
MRI 
(cUSS where 
MRI 
unavailable)  
 
 Focal subtle 
abnormalities of 
BG with normal 
appearance of the 
PLIC  
 Periventricular 
white matter 
changes difficult 
to differentiate 
from normal 
appearances and 
therefore not 
classified as 
abnormal 
 Changes confined 
to cerebral cortex 
and subcortical 
 Multi-focal 
lesions in 
BG with 
equivocal 
or abnormal 
signal 
intensity 
within 
PLIC  
 Small focal 
lesions of 
without loss 
of GM/WM 
differentiati
on 
 
 Widespread 
abnormalities 
involving all 
BGT structures 
and PLIC  
 Larger areas of 
abnormality with 
loss of GM/WM 
differentiation, 
consistent with 
infarction  
 Central grey 
matter 
hyperechogenicit
y ± more 
extensive 
cortical and 
21 
 
WM subcortical 
hyperechogenicit
y 
Term infarction  
MRI 
(cUSS where 
MRI 
unavailable) 
  Focal, non-
territorial 
infarct 
 
 Territorial infarct 
 
cUSS, cranial ultrasound scan; IVH, intraventricular haemorrhage; VIn, ventricular index; 
TEA, term-equivalent age; CGA, corrected gestational age; PVL, periventricular 
lecuomalacia; PVHI, periventricular haemorrhage infarction; BG, basal ganglia; MRI, 
magnetic resonance imaging; PLIC, posterior limb of the internal capsule; WM, white matter; 
GM, grey matter; BGT, basal ganglia–thalamus. 
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Table II: Active ingredients in the treatment and control supplement (in 2g powder) 
Component Amount in 2g powder 
Treatment Control 
Docosahexaenoic acid (mg) 37.8  0.4  
Eicosapentaenoic acid (mg) 7.8  0.08  
Arachidonic acid (mg) 4.4  0.02  
Uridine monophosphate (mg) 1.8  0 
Cytidine monophosphate (mg) 1.8  0 
Choline (mg) 10.5  1.38  
Vitamin B12 (μg) 0.12  0.02  
Zinc (mg) 0.76  0.06  
Iodine (μg) 15  0.6  
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Table III: Baseline characteristics of randomized participants 
 Treatment Control 
Numbers assigned treatment 29 30 
Sex (male/female) 17/12 17/13 
Gestation (<31 weeks/31–40weeks and 28 days) 14/15 14/16 
Mean (SD) gestational age at birth (wk) 32.9 (6.06) 33.7 (6.64) 
Neurological damage (mild/moderate/severe) 12/7/10 11/9/10 
Median (IQR) birthweight (g) 2095 (950–
3040) 
2278 (948–
3718) 
Mean (SD) head circumference (cm) 35.6 (2.52) 36.3 (3.09) 
Maternal educational qualification (qualification at 16y/at 
18y/tertiary-level education) 
3/4/17 1/8/9 
Mean (SD) corrected age at baseline (wk) 2.25 (2.67) 3.32 (4.37) 
Mean (SD) CCS-Bayley-III  74.29 (13.86) 77.78 
(12.81) 
Mean (SD) LCS-Bayley-III 66.39 (9.50) 68.48 
(10.79) 
Mean (SD) MCS-Bayley-III 82.00 (9.20) 82.93 
(11.46) 
Data are n unless otherwise indicated. IQR, interquartile range; CCS, cognitive composite 
score; Bayley-III, Bayley Scales of Infant Development, Third Edition; LCS, language 
composite score; MCS, motor composite score.  
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Table IV: Comparison of Bayley Scales of Infant Development, Third Edition (Bayley-III), 
composite domain standard scores by group and visit 
Outcome 
measure 
Trial 
visit 
(mo) 
Number includeda Mean score (SD) Difference in mean scores (95% 
CI) 
 
    
  Treatment Control Treatment Control Unadjustedb Adjustedc 
CCS-Bayley-
III 
12 24 21 85.2  
(18.1) 
82.4 
(20.1) 
3.7  
(–6.4 to 13.8) 
4.4  
(–4.7 to 13.4) 
24 24 19 87.7  
(20.4) 
81.6 
(18.5) 
8.3  
(–1.9 to 18.6) 
9.0  
(–0.2 to 18.2) 
LCS-Bayley-
III  
12 24 21 77.6  
(14.6) 
74.6 
(12.0) 
3.2  
(–6.2 to 12.7) 
2.7  
(–6.7 to 12.1) 
24 24 19 91.5  
(20.1) 
83.2 
(19.6) 
9.0  
(–0.6 to 18.6) 
8.6  
(–1.1 to 18.2) 
MCS-
Bayley-III  
12 24 20 79.6  
(18.3) 
80.0 
(21.4) 
0.1  
(–11.6 to 11.8) 
–0.2 (–10.6 to 
10.3) 
24 23 19 77.8  
(21.8) 
78.8 
(21.6) 
–1.5  
(–13.4 to 10.4) 
–1.2 (–11.9 to 
9.5) 
aAll participants included in analysis have a measurement for Bayley composite domain 
standard score at baseline and at least one other time point. bUnadjusted analyses are adjusted 
for visit and the interaction between treatment and visit. cAdjusted for baseline measurement, 
treatment, visit, interaction between treatment and visit, and the minimization factors of 
neurological severity, sex, and length of gestation. CI, confidence interval; CCS, cognitive 
composite score; LCS, language composite score; MCS, motor composite score. 
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Figure 1: Trial CONSORT flowchart. 
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Figure 2: Adjusted mean difference in treatment and control groups by visit for the Bayley 
Scales of Infant Development, Third Edition, composite cognitive (CCS), language (LCS), 
and motor score (MCS), and Vineland Adaptive Behavior Scale, Second Edition (VABS-II), 
domain standard score. CI, confidence interval. 
 
